|
JP5972176B2
(ja)
*
|
2010-02-23 |
2016-08-17 |
サノフイ |
抗アルファ２インテグリン抗体及びそれらの使用
|
|
TWI560199B
(en)
|
2010-08-31 |
2016-12-01 |
Sanofi Sa |
Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
|
|
PH12013501201A1
(en)
*
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
WO2012096975A2
(en)
*
|
2011-01-13 |
2012-07-19 |
The Board Of Trustees Of The Leland Stanford Junior University |
Method of predicting responsiveness of b cell lineage malignancies to active immunotherapy
|
|
AU2012235758B2
(en)
|
2011-03-25 |
2015-05-07 |
IGI Therapeutics SA |
Hetero-dimeric immunoglobulins
|
|
CN107915775B
(zh)
|
2011-07-11 |
2022-07-12 |
伊克诺斯科学公司 |
结合ox40的抗体及其用途
|
|
SI2744515T1
(sl)
|
2011-08-16 |
2022-05-31 |
Morphosys Ag |
Kombinirana terapija s protitelesom proti CD19 in dušikovim iperitom
|
|
AU2012296905B2
(en)
|
2011-08-16 |
2017-01-05 |
Incyte Corporation |
Combination therapy with an anti - CD19 antibody and a purine analog
|
|
AU2013322710A1
(en)
|
2012-09-25 |
2015-04-16 |
Glenmark Pharmaceuticals S.A. |
Purification of hetero-dimeric immunoglobulins
|
|
EP2839860B1
(en)
|
2012-10-12 |
2019-05-01 |
MedImmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
DK2906298T3
(en)
|
2012-10-12 |
2018-12-17 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
|
AU2013328625B2
(en)
|
2012-10-12 |
2016-12-15 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
JP2016503818A
(ja)
|
2013-01-02 |
2016-02-08 |
グレンマーク ファーマシューティカルズ， エセ．アー． |
Ｔｌ１ａと結合する抗体およびその使用
|
|
AU2014240083C1
(en)
|
2013-03-15 |
2019-10-24 |
Celgene Corporation |
Modified T lymphocytes
|
|
UY35468A
(es)
*
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
US10150814B2
(en)
|
2013-06-27 |
2018-12-11 |
Abbvie Biotherapeutics Inc. |
Fc variants with improved complement activation
|
|
EP3054985B1
(en)
|
2013-10-11 |
2018-12-26 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
MX389160B
(es)
*
|
2013-10-31 |
2025-03-20 |
Hutchinson Fred Cancer Res |
Células no t efectoras y madre/progenitoras hematopoyéticas modificadas y usos de estas.
|
|
EP3176185A1
(en)
|
2013-11-04 |
2017-06-07 |
Glenmark Pharmaceuticals S.A. |
Production of t cell retargeting hetero-dimeric immunoglobulins
|
|
RU2714902C2
(ru)
|
2013-12-19 |
2020-02-20 |
Новартис Аг |
Химерные рецепторы антигена против мезотелина человека и их применение
|
|
ES2876263T3
(es)
|
2014-04-07 |
2021-11-12 |
Novartis Ag |
Tratamiento del cáncer usando receptor de antígeno quimérico anti-cd19
|
|
US11041021B2
(en)
|
2014-05-23 |
2021-06-22 |
University Of Florida Research Foundation, Incorporated |
Car based immunotherapy
|
|
US10174095B2
(en)
|
2014-07-21 |
2019-01-08 |
Novartis Ag |
Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
|
|
TWI751102B
(zh)
*
|
2014-08-28 |
2022-01-01 |
美商奇諾治療有限公司 |
對ｃｄ１９具專一性之抗體及嵌合抗原受體
|
|
ES2688035T3
(es)
|
2014-08-29 |
2018-10-30 |
Gemoab Monoclonals Gmbh |
Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
|
|
GB201416112D0
(en)
|
2014-09-12 |
2014-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
WO2016061368A1
(en)
*
|
2014-10-15 |
2016-04-21 |
The Children's Hospital Of Philadelphia |
Compositions and methods for treating b-lymphoid malignancies
|
|
MA41480A
(fr)
|
2014-10-17 |
2017-12-19 |
Glenmark Pharmaceuticals Sa |
Anticorps qui se lient au ccr6 et leurs utilisations
|
|
US11773166B2
(en)
|
2014-11-04 |
2023-10-03 |
Ichnos Sciences SA |
CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
|
|
WO2016090190A1
(en)
|
2014-12-03 |
2016-06-09 |
Juno Therapeutics, Inc. |
Methods and compositions for adoptive cell therapy
|
|
US12428483B2
(en)
*
|
2014-12-22 |
2025-09-30 |
Systimmune, Inc. |
Bispecific tetravalent antibodies and methods of making and using thereof
|
|
US11248058B2
(en)
*
|
2015-02-19 |
2022-02-15 |
University Of Florida Research Foundation, Inc. |
Chimeric antigen receptors and uses thereof
|
|
GB201503742D0
(en)
*
|
2015-03-05 |
2015-04-22 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
HUE059218T2
(hu)
|
2015-04-08 |
2022-11-28 |
Novartis Ag |
CD20-terápiák, CD22-terápiák és kombinációs terápiák CD19 kiméra antigénreceptort (CAR-t) expresszáló sejttel
|
|
WO2016168769A1
(en)
*
|
2015-04-15 |
2016-10-20 |
The California Institute For Biomedical Research |
Chimeric receptor t cell switches for her2
|
|
EP3288569A4
(en)
*
|
2015-04-29 |
2018-12-19 |
Fred Hutchinson Cancer Research Center |
Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
|
|
CN114634943A
(zh)
|
2015-05-18 |
2022-06-17 |
T细胞受体治疗公司 |
使用融合蛋白对tcr重编程的组合物和方法
|
|
CA2986175A1
(en)
|
2015-05-26 |
2016-12-01 |
Morphosys Ag |
Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
|
|
US10493139B2
(en)
|
2015-07-24 |
2019-12-03 |
Innovative Cellular Therapeutics CO., LTD. |
Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
|
|
WO2017015783A1
(en)
*
|
2015-07-24 |
2017-02-02 |
Shanghai Sidansai Biotechnology Co., Ltd |
Humanized anti-cd19 antibody and use thereof
|
|
WO2018126369A1
(en)
|
2017-01-05 |
2018-07-12 |
Shanghai Sidansai Biotechnology Co., Ltd |
Humanized anti-cd19 antibody and use thereof with chimeric antigen receptor
|
|
AU2016311136B2
(en)
|
2015-08-21 |
2022-02-17 |
Incyte Corporation |
Combinations and uses thereof
|
|
MA44909A
(fr)
|
2015-09-15 |
2018-07-25 |
Acerta Pharma Bv |
Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
|
|
AR106188A1
(es)
*
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
EP3913000A1
(en)
*
|
2015-10-02 |
2021-11-24 |
F. Hoffmann-La Roche AG |
Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
|
|
ES2928167T3
(es)
*
|
2015-12-03 |
2022-11-15 |
Juno Therapeutics Inc |
Composiciones y métodos para reducir las respuestas inmunitarias contra receptores de antígenos quiméricos
|
|
EP3383892B1
(en)
|
2015-12-03 |
2022-12-21 |
Juno Therapeutics, Inc. |
Modified chimeric receptors and related compositions and methods
|
|
GB201601431D0
(en)
|
2016-01-26 |
2016-03-09 |
Medimmune Ltd |
Pyrrolobenzodiazepines
|
|
GB201602356D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
GB201602359D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
GB201607478D0
(en)
|
2016-04-29 |
2016-06-15 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
MA45124B1
(fr)
|
2016-05-30 |
2021-05-31 |
Morphosys Ag |
Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients
|
|
CN115998859A
(zh)
|
2016-06-27 |
2023-04-25 |
莫佛塞斯公司 |
抗-cd19抗体制剂
|
|
CA3039646A1
(en)
|
2016-10-07 |
2018-04-12 |
Novartis Ag |
Chimeric antigen receptors for the treatment of cancer
|
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
|
JP7100028B2
(ja)
|
2016-10-20 |
2022-07-12 |
セルジーン コーポレイション |
セレブロン系のヘテロ二量体化可能なキメラ抗原受容体
|
|
IL266216B2
(en)
|
2016-10-28 |
2023-09-01 |
Morphosys Ag |
Combination of anti-cd19 antibody with bcl-2 inhibitor and uses thereof
|
|
CA3044593A1
(en)
|
2016-11-22 |
2018-05-31 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
IL266892B2
(en)
|
2016-12-02 |
2025-10-01 |
Univ Southern California |
Artificial immune receptors and methods of using them
|
|
PL3544636T3
(pl)
|
2017-02-08 |
2021-12-06 |
Adc Therapeutics Sa |
Koniugaty pirolobenzodiazepina-przeciwciało
|
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
|
CN106967171B
(zh)
*
|
2017-02-23 |
2021-04-27 |
郑州大学 |
一种全人源重组CD40L单抗Fab片段及其制备方法
|
|
SMT202200490T1
(it)
|
2017-04-18 |
2023-01-13 |
Medimmune Ltd |
Coniugati di pirrolobenzodiazepina
|
|
AU2018256436B2
(en)
|
2017-04-19 |
2024-12-05 |
Board Of Regents, The University Of Texas System |
Immune cells expressing engineered antigen receptors
|
|
JOP20180042A1
(ar)
*
|
2017-04-24 |
2019-01-30 |
Kite Pharma Inc |
نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
|
|
JP2020519285A
(ja)
|
2017-05-10 |
2020-07-02 |
ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー |
最適化された核酸抗体構築物
|
|
PL3630177T3
(pl)
|
2017-05-31 |
2024-04-08 |
Morphosys Ag |
Paradygmat leczenia dla leczenia skojarzonego przeciwciałem anty-cd19 i wenetoklaksem
|
|
BR112019026564A2
(pt)
|
2017-06-14 |
2020-06-30 |
Adc Therapeutics Sa |
regimes de dosagem para a administração de um adc anti-cd19
|
|
WO2019011918A1
(en)
|
2017-07-10 |
2019-01-17 |
International - Drug - Development - Biotech |
TREATMENT OF LYMPHOCYTE B MALIGNANCIES USING AFUCOSYLATED PRO-APOPTOTIC ANTI-CD19 ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES OR CHEMOTHERAPEUTIC AGENTS
|
|
CA3099487A1
(en)
*
|
2017-07-20 |
2019-01-24 |
Nbe-Therapeutics Ag |
Human antibodies binding to ror2
|
|
SMT202200225T1
(it)
|
2017-08-18 |
2022-07-21 |
Medimmune Ltd |
Coniugati di pirrolobenzodiazepina
|
|
AU2018336520B2
(en)
|
2017-09-21 |
2025-03-27 |
WuXi Biologics Ireland Limited |
Novel anti-CD19 antibodies
|
|
EP3703675A4
(en)
|
2017-10-30 |
2021-06-16 |
Neuropore Therapies, Inc. |
SUBSTITUTED PHENYLSULFONYLPHÉNYLTRIAZOLETHIONES AND ASSOCIATED USES
|
|
CN111465616B
(zh)
*
|
2017-12-06 |
2023-08-01 |
艾克隆株式会社 |
特异性识别恶性b细胞的抗体或其抗原结合片段、包含其的嵌合抗原受体及其用途
|
|
CN111542541B
(zh)
*
|
2017-12-22 |
2023-11-03 |
艾克隆株式会社 |
特异性识别恶性b细胞的抗体或其抗原结合片段、包含其的嵌合抗原受体及其用途
|
|
CN109053899B
(zh)
*
|
2017-12-22 |
2021-11-16 |
湖南远泰生物技术有限公司 |
一种含人转铁蛋白抗原表位序列的嵌合体抗原受体
|
|
CN108047332B
(zh)
*
|
2018-01-15 |
2021-08-24 |
阿思科力(苏州)生物科技有限公司 |
以cd19为靶点的特异性抗体、car-nk细胞及其制备和应用
|
|
EP3755349A4
(en)
|
2018-02-21 |
2021-11-17 |
Board of Regents, The University of Texas System |
PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES
|
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
MY208825A
(en)
|
2018-06-13 |
2025-05-30 |
Novartis Ag |
Bcma chimeric antigen receptors and uses thereof
|
|
KR20200030337A
(ko)
|
2018-09-12 |
2020-03-20 |
주식회사 녹십자랩셀 |
종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
|
|
CN109293774B
(zh)
*
|
2018-10-16 |
2021-05-28 |
南京医科大学 |
特异性结合cd19的全人源化抗体及应用
|
|
CN116726362A
(zh)
|
2018-11-19 |
2023-09-12 |
比奥拉治疗股份有限公司 |
用生物治疗剂治疗疾病的方法和装置
|
|
JP7386382B2
(ja)
|
2018-12-12 |
2023-11-27 |
カイト ファーマ インコーポレイテッド |
キメラ抗原受容体及びｔ細胞受容体並びに使用方法
|
|
JP7090780B2
(ja)
*
|
2018-12-21 |
2022-06-24 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｃｄ３に結合する抗体
|
|
US11672858B2
(en)
|
2018-12-21 |
2023-06-13 |
Hoffmann-La Roche Inc. |
Bispecific antibody molecules binding to CD3 and TYRP-1
|
|
CN118546959A
(zh)
|
2019-03-05 |
2024-08-27 |
恩卡尔塔公司 |
Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
|
|
AU2020242747B2
(en)
|
2019-03-15 |
2025-09-18 |
Medimmune Limited |
Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer
|
|
CN114341176A
(zh)
*
|
2019-04-08 |
2022-04-12 |
纪念斯隆凯特琳癌症中心 |
Cd19抗体及其使用方法
|
|
EA202192975A1
(ru)
*
|
2019-04-30 |
2022-02-01 |
Криспр Терапьютикс Аг |
Аллогенная клеточная терапия b-клеточных злокачественных новообразований с применением генетически сконструированных т-клеток, нацеливающихся на cd19
|
|
MX2021013101A
(es)
|
2019-05-03 |
2022-01-04 |
Morphosys Ag |
Terapia anti-cd19 en pacientes que tienen una cantidad limitada de células nk.
|
|
KR20220026586A
(ko)
*
|
2019-06-27 |
2022-03-04 |
크리스퍼 테라퓨틱스 아게 |
암 치료를 위한 키메라 항원 수용체 t세포 및 nk세포 억제제의 용도
|
|
AU2020311511B2
(en)
|
2019-07-09 |
2024-08-29 |
Beijing Solobio Genetechnology Co., Ltd. |
Antibodies specifically recognizing Pseudomonas PcrV and uses thereof
|
|
CN110396129B
(zh)
*
|
2019-07-10 |
2020-11-24 |
武汉思安医疗技术有限公司 |
人源化cd19抗原结合单链抗体及其嵌合抗原受体、免疫细胞和应用
|
|
JP2022550435A
(ja)
|
2019-10-04 |
2022-12-01 |
ウルトラジェニックス ファーマシューティカル インコーポレイテッド |
組換えａａｖの改善された治療的使用のための方法
|
|
US20210130461A1
(en)
|
2019-10-31 |
2021-05-06 |
Morphosys Ag |
Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells
|
|
IL317199A
(en)
|
2019-10-31 |
2025-01-01 |
Morphosys Ag |
Anti-CD19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
|
|
PH12022551291A1
(en)
|
2019-11-26 |
2023-11-20 |
Novartis Ag |
Chimeric antigen receptors binding bcma and cd19 and uses thereof
|
|
CN115666704B
(zh)
|
2019-12-13 |
2025-09-26 |
比特比德科有限责任公司 |
用于将治疗剂递送至胃肠道的可摄取装置
|
|
CN115279795A
(zh)
*
|
2020-02-11 |
2022-11-01 |
克里斯珀医疗股份公司 |
靶向抗cd19嵌合抗原受体的抗独特型抗体
|
|
US20210340524A1
(en)
*
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
MX2022016069A
(es)
|
2020-06-19 |
2023-02-02 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y cd19.
|
|
CN115956088A
(zh)
|
2020-06-22 |
2023-04-11 |
莫佛塞斯公司 |
包括抗-CD19抗体和阻断SIRPα-CD47先天免疫检查点的多肽的抗肿瘤组合疗法
|
|
IL301865A
(en)
|
2020-10-06 |
2023-06-01 |
Xencor Inc |
Biomarkers, methods, and compositions for treating autoimmune disease including systemic lupus erythematous (sle)
|
|
CN116848147A
(zh)
*
|
2020-11-20 |
2023-10-03 |
先声再明医药有限公司 |
Cd19人源化抗体及其应用
|
|
US20220184208A1
(en)
|
2020-12-04 |
2022-06-16 |
Morphosys Ag |
Anti-cd19 combination therapy
|
|
US20240425563A1
(en)
*
|
2021-01-13 |
2024-12-26 |
Washington University |
MHC-INDEPENDENT TCRs AND METHODS OF MAKING AND USING SAME
|
|
CN112679612B
(zh)
*
|
2021-01-29 |
2022-07-01 |
武汉华美生物工程有限公司 |
抗cd19人源化抗体及其制备方法与应用
|
|
US20240270842A1
(en)
*
|
2021-05-07 |
2024-08-15 |
Viela Bio, Inc |
Use of an anti-cd19 antibody to treat myasthenia gravis
|
|
WO2023073645A1
(en)
|
2021-10-29 |
2023-05-04 |
Takeda Pharmaceutical Company Limited |
Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
|
|
US20250084169A1
(en)
|
2022-01-12 |
2025-03-13 |
Biomolecular Holdings Llc |
Nk/monocyte engagers
|
|
JP2025528837A
(ja)
|
2022-08-17 |
2025-09-02 |
インサイト・コーポレイション |
抗ｃｄ１９抗体及びｅｚｈ２モジュレーターを含む治療
|
|
WO2024222859A1
(zh)
*
|
2023-04-28 |
2024-10-31 |
深圳深信生物科技有限公司 |
经修饰的递送载体及其应用
|
|
WO2024251263A1
(en)
|
2023-06-09 |
2024-12-12 |
Jw Therapeutics R & D (Shanghai) Co., Ltd. |
Fusion protein and medical use thereof
|
|
US20250197501A1
(en)
*
|
2023-12-19 |
2025-06-19 |
Development Center For Biotechnology |
Recombinant antibody, immunoconjugate comprising the same, and uses thereof in treating cancers
|